Loading...

FITC anti-mouse CD8a Antibody

Pricing & Availability
Clone
53-6.7 (See other available formats)
Regulatory Status
RUO
Other Names
T8, Lyt2, Ly-2
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
53-6.7_FITC_102110
C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) FITC (filled histogram) or rat IgG2a, κ FITC isotype control (open histogram).
  • 53-6.7_FITC_102110
    C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) FITC (filled histogram) or rat IgG2a, κ FITC isotype control (open histogram).
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
100705 50 µg 24€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100706 500 µg 80€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The CD8a antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Application References

(PubMed link indicates BioLegend citation)
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  30. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Sun L, et al. 2021. Cancer Cell. 39:1361. PubMed
  2. Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed
  3. Liu J, et al. 2019. Immunity. 50:600. PubMed
  4. Strickley JD, et al. 2019. Nature. 575:519. PubMed
  5. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  6. Petrova T, et al. 2020. Sci Rep. 10:3479. PubMed
  7. Xiang G, et al. 2022. Cell Death Dis. 13:451. PubMed
  8. Wu MJ, et al. 2022. Cancer Discov. 12:812. PubMed
  9. Yao RQ, et al. 2022. Theranostics. 12:4606. PubMed
  10. Gerwing M, et al. 2020. Mol Imaging Biol. 1.959027778. PubMed
  11. Han X, et al. 2017. Int J Mol Sci. 10.3390/ijms18050942. PubMed
  12. Furuta Y, et al. 2017. PLoS One. 12(2):e0172509. PubMed
  13. Kawano H, et al. 2016. Int Immunol. 28: 489 - 501. PubMed
  14. Liu W, et al. 2020. Mol Ther Oncolytics. 17:350. PubMed
  15. Lin W, et al. 2020. Theranostics. 10:4871. PubMed
  16. Yang H, et al. 2019. Mol Metab. 23:24. PubMed
  17. Taddeo A, et al. 2022. NPJ Vaccines. 7:82. PubMed
  18. Schönberger K, et al. 2022. Cell Stem Cell. 29:131. PubMed
  19. Paschall A, et al. 2015. J Immunol. 194: 2369-2379. PubMed
  20. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  21. Ren S, et al. 2019. Oncol Rep. 41:1509. PubMed
  22. Lee H, et al. 2020. Cell Metabolism. 31(4):822-836. PubMed
  23. Seo YB, et al. 2021. Vaccines (Basel). 9: . PubMed
  24. Zhang J, et al. 2021. MedComm (Beijing). 2:256. PubMed
  25. Altshuler A, et al. 2021. Cell Stem Cell. 28(7):1248-1261.e8. PubMed
  26. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  27. Hao B, et al. 2015. J Exp Med. 212:809. PubMed
  28. Apte S, et al. 2010. J Immunol. 185:998. PubMed
  29. Gotoh K et al. 2018. Cell reports. 25(7):1800-1815 . PubMed
  30. Greenberg J, et al. 2022. JCI Insight. Online ahead of print. PubMed
  31. Mayer RL, et al. 2022. Nat Commun. 13:6075. PubMed
  32. Yang X, et al. 2020. Blood Sci. 2:89. PubMed
  33. Wang Q, et al. 2020. Wound Repair Regen. 28:105. PubMed
  34. Castellanos CA, et al. 2021. Sci Immunol. 6:eabh0707. PubMed
  35. Morales D, et al. 2015. J Virol. 89:337. PubMed
  36. Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed
  37. Lutes LK, et al. 2021. eLife. 10:00. PubMed
  38. Okamoto T, et al. 2020. Cancer Res. 3580:80. PubMed
  39. Wang X, et al. 2021. Front Cell Dev Biol. 632805:9. PubMed
  40. Luff DH, et al. 2021. Front Immunol. 631271:12. PubMed
  41. Brooks JF, et al. 2020. Cytotherapy. 22:436. PubMed
  42. Antonia O Cuff et al. 2017. Wellcome open research. 2:39 . PubMed
  43. Pham THM, et al. 2020. Cell Host & Microbe. 27(1):54-67.e5.. PubMed
  44. Treger RS, et al. 2020. Immunity. 50(2):334-347.e9.. PubMed
  45. Yoon Y, et al. 2021. Cancers (Basel). 13: . PubMed
  46. Shi S, et al. 2020. Clin Cancer Res. 26:5990. PubMed
  47. Wang Y, et al. 2022. Acta Pharm Sin B. 12:262. PubMed
  48. Wu K, et al. 2021. Aging (Albany NY). 13:. PubMed
  49. Mukherjee D, et al. 2022. Nat Commun. 13:3747. PubMed
  50. Xiong A, et al. 2022. EBioMedicine. 83:104239. PubMed
  51. Tu X, et al. 2022. Nat Commun. 13:6977. PubMed
  52. Magod P, et al. 2021. Cell Reports. 36(5):109480. PubMed
  53. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  54. Lv H, et al. 2020. Cell Metabolism. 33(1):110-127.e5. PubMed
  55. Artinger K, et al. 2015. PLoS One. 10: 0135087. PubMed
  56. Shade K, et al. 2015. J Exp Med. 212:457. PubMed
  57. DeBerge M, et al. 2013. PLoS One. 8:79340. PubMed
  58. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  59. Dodagatta-Marri E, et al. 2021. Cell Rep. 36:109309. PubMed
  60. Suah AN, et al. 2021. J Clin Invest. 131:. PubMed
  61. Cousin N, et al. 2021. Cancer Res. 81:4133. PubMed
  62. Nicolay N, et al. 2016. Sci Rep. 6: 26645. PubMed
  63. Velázquez K, et al. 2016. Am J Physiol Gastrointest Liver Physiol. 311: G699 - G712. PubMed
  64. Zhang F, et al. 2019. Immunity. 50:738. PubMed
  65. Wang F, et al. 2021. Cell Mol Gastroenterol Hepatol. 13:257. PubMed
  66. MacDonald A, et al. 2021. Front Immunol. 12:755995. PubMed
  67. Zebley CC, et al. 2021. Cell Rep. 37:109796. PubMed
  68. Yu Y, et al. 2022. Nat Commun. 13:6357. PubMed
  69. Wu J, et al. 2020. Immunity. 53:115. PubMed
  70. Köchl R, et al. 2020. Elife. 9:00. PubMed
  71. Len-Letelier RA, et al. 2020. Frontiers in Immunology. 11:583382. PubMed
  72. Maluski M, et al. 2019. J Clin Invest. 129:5108. PubMed
  73. Xiao P, et al. 2019. J Exp Med. 216:337. PubMed
  74. Topper MJ et al. 2017. Cell. 171(6):1284-1300 . PubMed
  75. Li Y, et al. 2019. Sci Rep. 9:6932. PubMed
  76. Wu L, et al. 2022. Theranostics. 12:842. PubMed
  77. Gu Y, et al. 2021. Cell Res. Online ahead of print. PubMed
  78. Zhang B, et al. 2021. Nat Biomed Eng. 5:1288. PubMed
  79. Aebischer D, et al. 2014. PLoS One. 9:99297. PubMed
  80. Drees J, et al. 2015. Anticancer Res. 35:843. PubMed
  81. Lu X, et al. 2016. Nat Commun. 7: 12719. PubMed
  82. Xie Z, et al. 2020. Light Sci Appl. 0.486805556. PubMed
  83. Li Y, et al. 2020. Cell Stem Cell. 27(5):732-747.e7. PubMed
  84. Crowe JL, et al. 2020. Proc Natl Acad Sci U S A. 22953:117. PubMed
  85. Webster P, et al. 2018. Nat Commun. 9:2649. PubMed
  86. Niemann J, et al. 2019. Nat Commun. 10:3236. PubMed
  87. Srivastava S, et al. 2019. Cancer Cell. 35:489. PubMed
  88. Wu Y, et al. 2021. Nat Commun. 12:2346. PubMed
  89. Pishesha N, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  90. Volberding PJ, et al. 2021. Cell Reports. 35(8):109160. PubMed
  91. Tacconi C, et al. 2021. Cell Reports. 35(2):108993. PubMed
  92. Yang J, et al. 2020. Nature. 586:572. PubMed
  93. Knocke S, et al. 2016. Cell Rep. 17:2234-2246. PubMed
  94. Ito C, et al. 2015. PLoS One. 10: e0140808. PubMed
  95. Wu S, et al. 2014. Clin Vaccine Immunol. 21:156. PubMed
  96. Wan X, et al. 2018. Nature. 560:107. PubMed
  97. Qi S et al. 2016. eLife. 5 pii: e14756. PubMed
  98. Budida R, et al. 2017. Eur J Immunol. 47:1819. PubMed
  99. Kim JH, et al. 2019. Mol Med. 25:33. PubMed
  100. Ren Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  101. Trefzer A, et al. 2021. Cell Reports. 34(6):108748. PubMed
  102. Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed
  103. Fang Y, et al. 2019. Aging (Albany NY). 11:4910. PubMed
  104. Horkova V, et al. 2020. Cell Reports. 30(5):1504-1514.e7.. PubMed
  105. Du J, et al. 2018. AMB Express. 8:158. PubMed
  106. Holman P, et al. 2005. J Immunol. 174:3986. PubMed
  107. Huang Z, et al. 2021. Nat Commun. 12:145. PubMed
  108. Grioni M, et al. 2021. Blood Adv. 5:2817. PubMed
  109. Matundan HH, et al. 2021. J Virol. 95:e0103621. PubMed
  110. Bosnjak B, et al. 2021. Front Immunol. 12:772240. PubMed
  111. Sun C, et al. 2022. J Adv Res. 35:71. PubMed
  112. Dey S, et al. 2020. J Immunother Cancer. 8:. PubMed
  113. Zheng D, et al. 2022. Acta Pharm Sin B. 12:2740. PubMed
  114. Liu B, et al. 2022. Mol Med Rep. 26:. PubMed
  115. Nikolos F, et al. 2022. Nat Commun. 13:1487. PubMed
  116. Yan J, et al. 2020. Cell Rep. 107820:31. PubMed
  117. Yi W, et al. 2021. Cell Reports. 34(13):108922. PubMed
  118. Shen JZ, et al. 2020. Cell. 184(2):352-369.e23. PubMed
  119. Li X, et al. 2020. Nat Commun. 4.877777778. PubMed
  120. Denny JE, et al. 2019. Sci Rep. 2.786111111. PubMed
  121. Landon J Edgar et al. 2018. Cell chemical biology. 26(1):131-136 . PubMed
  122. Chatterjee S et al. 2017. Cell metabolism. 27(1):85-100 . PubMed
  123. Wang R, et al. 2022. Front Immunol. 13:947756. PubMed
  124. Jin C, et al. 2022. Oncoimmunology. 11:2099642. PubMed
  125. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  126. Daneshmandi S, et al. 2021. Elife. 10:. PubMed
  127. Huang L, et al. 2021. Breast Cancer Res Treat. Online ahead of print. PubMed
  128. Wang L, et al. 2015. Cancer Immunol Res. 3: 1030-1041. PubMed
  129. Li Y, Kaneda T 2016. Sci Rep. 6: 25077. PubMed
  130. Perry JL, et al. 2020. ACS Nano. 5.583333333. PubMed
  131. Blagih J, et al. 2020. Cell Rep. 30:481. PubMed
  132. Fu S, et al. 2020. Nat Commun. 0.7625. PubMed
  133. Tao Z, et al. 2019. Clin Cancer Res. 25:1113. PubMed
  134. Zhang NN, et al. 2020. Cell. 182(5):1271-1283. PubMed
  135. Bartolacci C, et al. 2018. Cancer Immunol Res. 1.281944444. PubMed
  136. Riedl P, et al. 2009. J Immunol. 183:370. PubMed
  137. Zhan L, et al. 2022. Cancer Lett. 529:37. PubMed
  138. Tsukui H, et al. 2020. BMC Cancer. 20:411. PubMed
  139. Chen R, et al. 2021. Cell Reports. 34(7):108751. PubMed
  140. Kvell K, et al. 2014. Immunobiology. 219:644. PubMed
  141. Dulken BW, et al. 2019. Nature. 571:205. PubMed
  142. Hu Z, et al. 2020. PLoS One. 15:e0228339. PubMed
  143. Ibrahim ML, et al. 2018. Cell Rep. 25:3036. PubMed
  144. Feng D, et al. 2022. Nat Commun. 13:5554. PubMed
  145. He C, et al. 2022. Nat Commun. 13:5459. PubMed
  146. Li M, et al. 2021. Cancers (Basel). 13:. PubMed
  147. Berghoff SA, et al. 2021. Nat Neurosci. 24:47. PubMed
  148. Fang F, et al. 2021. Cell Rep. 37:109981. PubMed
  149. Shen L, et al. 2015. Cancer Immunol Res. 3:136. PubMed
  150. Calderon B, et al. 2015. J Exp Med. 212: 1497-1512. PubMed
  151. Yasuma K, et al. 2016. PLoS Pathog. 12: 1005372. PubMed
  152. Martina M, et al. 2016. J Am Soc Nephrol. 27: 1113-1123. PubMed
  153. Miura N, et al. 2017. Mol Ther. 10.1016/j.ymthe.2017.01.020. PubMed
  154. Daneshmandi S, et al. 2021. Cell Reports. 34(10):108831. PubMed
  155. Xia Y, et al. 2018. Cell. 175:1059. PubMed
  156. Urata S, et al. 2018. PLoS Pathog. 14:e1007172. PubMed
  157. Raju S, et al. 2020. Cell Reports. 29(9):2556-2564.e3.. PubMed
  158. Panigrahy D, et al. 2019. J Clin Invest. 130:2964. PubMed
  159. Wu P, et al. 2020. Cancer Immunol Res. 8:1470. PubMed
  160. Soria-Castro R, et al. 2020. Sci Rep. 10:17802. PubMed
  161. Roderick J, et al. 2014. Proc Natl Acad Sci U S A. 111:14436. PubMed
  162. Kos S, et al. 2019. PLoS One. 14:e0217762. PubMed
  163. Li Q, et al. 2022. Front Oncol. 12:841977. PubMed
  164. Kung YJ, et al. 2022. J Biomed Sci. 29:57. PubMed
  165. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  166. Ren Y, et al. 2021. Nat Commun. 12:5405. PubMed
  167. Porrello A, et al. 2018. Nat Commun. 9:1988. PubMed
  168. Sade–Feldman M, et al. 2018. Cell. 175:998. PubMed
  169. Golan K et al. 2018. Cell stem cell. 23(4):572-585 . PubMed
  170. Sivapatham S, et al. 2019. Front Immunol. 1.865277778. PubMed
  171. Royzman D, et al. 2019. Front Immunol. 10:633. PubMed
  172. Tsyklauri O, et al. 2021. EMBO Rep. 22:e50785. PubMed
  173. Petriv N, et al. 2021. Oncoimmunology. 10:1874159. PubMed
  174. Kim S, et al. 2022. Cancers (Basel). 14:. PubMed
  175. Zhang Z, et al. 2020. Nature. 579:415. PubMed
  176. Cané S, et al. 2021. J Immunother Cancer. 9:. PubMed
  177. Chakraborty P, et al. 2020. Cell Reports. 28(7):1879-1893.e7.. PubMed
  178. Fleskens V, et al. 2019. Cell Rep. 26:3600. PubMed
  179. Li K, et al. 2020. Nat Commun. 0.795138889. PubMed
  180. Burton OT, et al. 2018. Clin Exp Allergy. 48:288. PubMed
  181. Chryplewicz A, et al. 2022. Cancer Cell. 40:1111. PubMed
  182. Li X, et al. 2022. Oncoimmunology. 11:2118210. PubMed
  183. Li H, et al. 2022. iScience. 25:104481. PubMed
  184. Wang X, et al. 2022. Elife. 11:. PubMed
  185. D'Cruz L, et al. 2014. J Immunol. 192:2227. PubMed
  186. Katsuyama T, et al. 2021. Cell Reports. 36(1):109339. PubMed
  187. Wu L, et al. 2020. Cancer Immunol Res. 710:8. PubMed
  188. Su M, et al. 2018. Immunol Cell Biol. 9:2448. PubMed
  189. Hebbandi Nanjundappa R, et al. 2017. Cell. 171:655. PubMed
  190. Tanegashima K et al. 2017. EBioMedicine. 24:247-256 . PubMed
  191. Hong Y, et al. 2019. J Extracell Vesicles. 8:1670893. PubMed
  192. Kim YS, et al. 2018. Front Immunol. 9:1093. PubMed
  193. Wen X, et al. 2021. World J Gastroenterol. 27:2834. PubMed
  194. Wang K, et al. 2021. Nat Commun. 12:4558. PubMed
  195. Xie L, et al. 2020. Infect Immun. :88. PubMed
  196. Hayashi K, et al. 2020. Nat Commun. 4.832638889. PubMed
  197. Schlecker E, et al. 2012. J Immunol. 189:5602. PubMed
  198. Zhi Y, et al. 2020. Int J Mol Med. 45:1327. PubMed
  199. Bing Wu et al. 2018. Immunity. 49(5):886-898 . PubMed
  200. Li CY, et al. 2022. Int J Mol Sci. 23:. PubMed
  201. Ying B, et al. 2022. Sci Transl Med. 14:eabm3302. PubMed
  202. Lee S, et al. 2021. Autophagy. 18:1062. PubMed
  203. Song X, et al. 2022. Transl Oncol. 15:101306. PubMed
  204. Akhtar MN, et al. 2020. PLoS Pathog. 16:e1009136. PubMed
  205. Xie Z, et al. 2020. Light Sci Appl. 9:161. PubMed
  206. Gu Z, et al. 2021. Nat Genet. 53:672. PubMed
  207. Yang F, et al. 2021. Nat Commun. 12:3424. PubMed
RRID
AB_312744 (BioLegend Cat. No. 100705)
AB_312745 (BioLegend Cat. No. 100706)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
UniProt
View information about CD8alpha on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD8a Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD8a 53-6.7 FC
Biotin anti-mouse CD8a 53-6.7 FC,IHC
FITC anti-mouse CD8a 53-6.7 FC
PE anti-mouse CD8a 53-6.7 FC
PE/Cyanine5 anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC-F,IP
PE/Cyanine7 anti-mouse CD8a 53-6.7 FC
APC/Cyanine7 anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 488 anti-mouse CD8a 53-6.7 FC,3D IHC
Alexa Fluor® 647 anti-mouse CD8a 53-6.7 FC,IHC-F,3D IHC,SB
Pacific Blue™ anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 700 anti-mouse CD8a 53-6.7 FC
PerCP/Cyanine5.5 anti-mouse CD8a 53-6.7 FC
PerCP anti-mouse CD8a 53-6.7 FC
Brilliant Violet 421™ anti-mouse CD8a 53-6.7 FC,IHC,SB
Brilliant Violet 570™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 650™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 605™ anti-mouse CD8a 53-6.7 FC
Ultra-LEAF™ Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC,IP,Depletion,Block
Brilliant Violet 711™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 785™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 510™ anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a (Maxpar® Ready) 53-6.7 FC,CyTOF®
Alexa Fluor® 594 anti-mouse CD8a 53-6.7 IHC-F,FC,3D IHC
PE/Dazzle™ 594 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 750 anti-mouse CD8a 53-6.7 FC
GoInVivo™ Purified anti-mouse CD8a 53-6.7 FC
TotalSeq™-A0002 anti-mouse CD8a 53-6.7 PG
Spark Blue™ 550 anti-mouse CD8a 53-6.7 FC
Spark NIR™ 685 anti-mouse CD8a 53-6.7 FC
TotalSeq™-C0002 anti-mouse CD8a 53-6.7 PG
TotalSeq™-B0002 anti-mouse CD8a 53-6.7 PG
Spark YG™ 570 anti-mouse CD8a 53-6.7 IHC-F
PE/Fire™ 640 anti-mouse CD8a 53-6.7 FC
PE/Fire™ 700 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 574 anti-mouse CD8a Antibody 53-6.7 FC
Spark Violet™ 423 anti-mouse CD8a Antibody 53-6.7 FC
Spark UV™ 387 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 515 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark Red™ 718 anti-mouse CD8a (Flexi-Fluor™) 53-6.7 FC
Spark PLUS UV™ 395 anti-mouse CD8a 53-6.7 FC
Go To Top Version: 2    Revision Date: 01.21.2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account